Protocol Ledger

NCT06804811 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Interventional Phase III clinical trial protocol NCT06804811 sponsored by Incyte in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-13 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06804811
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06804811
Protocol FieldVerified Registry Value
NCT IdentifierNCT06804811
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2025-11-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06804811
Hospital Research SiteLocationSite Profile
Hospital Italiano de Buenos AiresBuenos Aires, ArgentinaOpen Hospital Dossier ->
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
Universitair Ziekenhuis LeuvenLeuven, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI